• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tela Bio lands $1m investment for surgical implants

March 27, 2018 By Sarah Faulkner

Tela BioPrivately-held Tela Bio said this week that it landed a $1 million investment from ProMedica, a not-for-profit healthcare group serving northwest Ohio and southern Michigan.

According to the deal, Tela Bio and ProMedica Innovations Venture Fund plan to strike a strategic relationship to educate surgical specialists at the ProMedica Hernia Center using Tela Bio’s regenerative surgical implants.

The first $500,000 will go to Tela Bio immediately, the company reported, and a second tranche will close contingent upon revenue milestones.

The Malvern, Pa.-based company’s device combines biologic and synthetic materials in an embroidered implant that allows fluid and cells to move freely. The implants are designed for ventral hernia repair and abdominal wall reconstruction. Tela Bio first launched its OviTex reinforced bioscaffold in July 2016.

“We are pleased to announce the agreement with ProMedica Innovations and look forward to partnering on new research and education programs,” Tela Bio’s president & CEO Antony Koblish said in prepared remarks. “Integrated delivery networks that have adopted OviTex products in place of other biologic and resorbable synthetic products have consistently experienced significant cost savings. This investment is further validation of our mission to improve patient care and surgical outcomes while reducing costs.”

“ProMedica Innovations is constantly seeking investments in healthcare companies that are positioned to improve clinical outcomes while reducing healthcare costs,” Dr. John Pigott, chief innovations officer of ProMedica, added. “We are eager to explore opportunities to partner on research and education with Tela Bio, which is a great example of such a company.”

In October last year, Tela Bio struck a deal with Pacira Pharmaceuticals (NSDQ:PCRX) that could bring the surgical reconstruction company as much as $25 million.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Implants, Surgical Tagged With: telabio

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS